Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.58 |
| ▸ | CPT2 | P23786 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | KDM4A | O75164 | 2/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798915 | 0.77 | ACLY (0.43) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL12524010 | 0.77 | ACLY (0.43) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL19258711 | 0.76 | ALDH1A1 (0.46) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL9251690 | 0.75 | CPT2 (0.41) | ACLYCPT2ALDH1A1TSHRTDP1 | |
| SCHEMBL4951671 | 0.75 | CPT2 (0.41) | ACLYCPT2ALDH1A1TSHRTDP1 | |
| SCHEMBL721435 | 0.73 | ACLY (1.00) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL17181757 | 0.73 | ACLY (1.00) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL17181773 | 0.73 | ACLY (1.00) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL6773065 | 0.73 | ACLY (1.00) | ACLYCPT2ALDH1A1CYP2D6TSHR | |
| SCHEMBL2110910 | 0.73 | ACLY (1.00) | ACLYCPT2ALDH1A1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170232013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH | 2017-08-17 | — | — | US | disclosed |
| US-9636352-B2 | Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2012125524-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170232013-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCULOSKELETAL RELATED DISEASES AND DISORDERS USING METAL ION-CITRATE ANALOG COMPLEXES | CS, ACLY, CA5A | ACLY 2/4885CPT2 288/4885ALDH1A1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.